NasdaqCM - BOATS Real Time Price USD

Oncolytics Biotech Inc. (ONCY)

0.4394 -0.0094 (-2.09%)

At close: November 6 at 4:00:00 PM EST

0.4400 +0.0006 (+0.14%)

Overnight: 8:02:11 PM EST

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for ONCY

Chart does not reflect overnight price.

57m ago Powered by Yahoo Scout

Oncolytics reported new translational data linking pelareorep with stronger immune activation and tumor responses in anal cancer. The company is also advancing registrational plans for colorectal cancer and expects additional GOBLET data, while limited cash and continued trial costs remain key financing considerations.

Previous Close 0.4488
Open 0.4550
Bid 0.3848 x 100
Ask 0.5550 x 500
Day's Range 0.4282 - 0.4582
52 Week Range 0.3800 - 1.3000
Volume 516,951
Avg. Volume 1,078,676
Market Cap (intraday) 57.614M
Beta (5Y Monthly) 1.24
PE Ratio (TTM) --
EPS (TTM) -0.3500
Earnings Date (est.) Nov 16, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 4.44
Moby Rating Neutral

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

oncolyticsbiotech.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ONCY

49.49%

S&P 500 (^GSPC)

7.76%

1-Year Return

ONCY

56.50%

S&P 500 (^GSPC)

9.77%

3-Year Return

ONCY

73.04%

S&P 500 (^GSPC)

68.96%

5-Year Return

ONCY

79.08%

S&P 500 (^GSPC)

57.04%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -13.14M

Profit Margin 0.00%

FY25

FY26

-10M

-5M

0.0%

Analyst Price Targets

2.87

4.44 Average

0.4394 Current

5.90 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 8/19/2026

Analyst HC Wainwright & Co.

Rating Action Maintains

Rating Buy

Price Action Lowers

Price Target 10 -> 5

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-211.24%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-37.46M
Diluted EPS (ttm)

-0.3500

Balance Sheet and Cash Flow

Total Cash (mrq)

4.12M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-12.01M

XERS Xeris Biopharma Holdings, Inc.

15.30 +15.83%

VTVT vTv Therapeutics Inc.

21.03 -4.09%

NNVC NanoViricides, Inc.

1.3200 +1.55%

BGMSP Bio Green Med Solution, Inc.

2.5000 -6.02%

BLRX BioLineRx Ltd.

1.7100 -9.50%

U.S. markets closed

Oncolytics Biotech Inc. (ONCY)

2.19%

-26.77%

-52.24%

-49.49%

-56.50%

-79.08%

-99.12%

What's happening with ONCY?

Oncolytics Biotech Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch